Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

13.02.25 20:08 Uhr

Werte in diesem Artikel
Aktien

108,04 EUR 0,24 EUR 0,22%

Filing of the 2024 U.S. Form 20-F and French "Document d’Enregistrement Universel” containing the Annual Financial Report

Wer­bung

Paris, February 13, 2025. Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its "Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF).

These documents are available on the company’s website:
https://www.sanofi.com/en/investors/reports-and-publications/financial-reports-and-regulated-information

Wer­bung

In addition, the Form 20-F is available on the website of the SEC (www.sec.gov) and the "Document d’Enregistrement Universel” is available on the website of the AMF (www.amf-france.org). A hard copy of these documents, each of which contains our complete audited financial statements, may be received free of charge, upon request.

About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Wer­bung

Media Relations
Sandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Victor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.com

Investor Relations
Thomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com
Alizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com
Felix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.com
Keita Browne | + 1 781 249 1766 | keita.browne@sanofi.com
Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com
Tarik Elgoutni | + 1 617 710 3587 | tarik.elgoutni@sanofi.com
Thibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com

Attachment


Ausgewählte Hebelprodukte auf Sanofi

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Sanofi

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Sanofi S.A.

Wer­bung

Analysen zu Sanofi S.A.

DatumRatingAnalyst
11.03.2025Sanofi OutperformBernstein Research
10.03.2025Sanofi BuyJefferies & Company Inc.
05.03.2025Sanofi BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
04.03.2025Sanofi HoldDeutsche Bank AG
20.02.2025Sanofi OutperformBernstein Research
DatumRatingAnalyst
11.03.2025Sanofi OutperformBernstein Research
10.03.2025Sanofi BuyJefferies & Company Inc.
05.03.2025Sanofi BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
20.02.2025Sanofi OutperformBernstein Research
13.02.2025Sanofi BuyUBS AG
DatumRatingAnalyst
04.03.2025Sanofi HoldDeutsche Bank AG
14.02.2025Sanofi NeutralJP Morgan Chase & Co.
31.01.2025Sanofi HoldDeutsche Bank AG
30.01.2025Sanofi NeutralJP Morgan Chase & Co.
24.01.2025Sanofi NeutralJP Morgan Chase & Co.
DatumRatingAnalyst
18.12.2024Sanofi SellDeutsche Bank AG
17.12.2024Sanofi SellDeutsche Bank AG
06.12.2024Sanofi SellDeutsche Bank AG
03.12.2024Sanofi SellDeutsche Bank AG
28.10.2024Sanofi SellDeutsche Bank AG

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Sanofi S.A. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen